Processa Pharmaceuticals, Inc. - FORM 8-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - October 11, 2017

Attached files

file filename
EX-99.2 - UNAUDITED INTERIM FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2017 - Processa Pharmaceuticals, Inc.pcsa_ex992.htm
EX-99.1 - FINANCIAL STATEMENTS AS OF DECEMBER 31, 2015 AND DECEMBER 31, 2016 AND FOR THE P - Processa Pharmaceuticals, Inc.pcsa_ex991.htm
EX-10.2 - FORM OF LOCK UP/LEAK OUT AGREEMENT - PROMET - Processa Pharmaceuticals, Inc.pcsa_ex102.htm
EX-10.1 - FORM OF LOCK UP AGREEMENT - HEATWURX - Processa Pharmaceuticals, Inc.pcsa_ex101.htm
8-K - CURRENT REPORT - Processa Pharmaceuticals, Inc.pcsa_8k.htm


[pcsa_ex231002.gif]



Consent of Independent Registered Public Accounting Firm


We hereby consent to the incorporation by reference in this filing on Form 8-K of our report dated September 15, 2017, of our audit of the financial statements of Promet Therapeutics, LLC as of December 31, 2016 and 2015, and for the year ended December 31, 2016 and the period from August 31, 2015 through December 31, 2015.



/s/ BD & Company, Inc.

Owings Mills, MD

October 11, 2017



















Processa Pharmaceuticals, Inc. Reports